U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07326709) titled 'A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease' on Jan. 07.
Brief Summary: The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Study Start Date: June 01, 2026
Study Type: INTERVENTIONAL
Condition:
Huntington Disease
Intervention:
DRUG: Votoplam (blinded)
Votoplam (blinded) ac...